Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Gross Margin (2016 - 2025)

Historic Gross Margin for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to 64.52%.

  • Niagen Bioscience's Gross Margin rose 10300.0% to 64.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.89%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 61.84% for FY2024, which is 10700.0% up from last year.
  • Latest data reveals that Niagen Bioscience reported Gross Margin of 64.52% as of Q3 2025, which was up 10300.0% from 65.0% recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Gross Margin registered a high of 65.0% during Q2 2025, and its lowest value of 57.23% during Q4 2022.
  • Its 5-year average for Gross Margin is 61.44%, with a median of 61.08% in 2021.
  • As far as peak fluctuations go, Niagen Bioscience's Gross Margin skyrocketed by 49500bps in 2021, and later plummeted by -39700bps in 2022.
  • Niagen Bioscience's Gross Margin (Quarter) stood at 61.2% in 2021, then fell by -6bps to 57.23% in 2022, then rose by 7bps to 61.04% in 2023, then grew by 2bps to 62.48% in 2024, then rose by 3bps to 64.52% in 2025.
  • Its Gross Margin stands at 64.52% for Q3 2025, versus 65.0% for Q2 2025 and 63.42% for Q1 2025.